. Increased Th17 cells mediate autoreactive inflammation and tissue destruction during RA development [5] [6] [7] [8] ,
whereas several types of Treg cells maintain tight regulation of T helper (Th) cells for preventing T cell-mediated autoimmunity and inflammatory damage [9] [10] [11] [12] . Recent studies have revealed a link between Treg and Th17 cells. Treg and Th17 cells may develop from the same precursors under distinct cytokine conditions [13] , and a subset of IL-17-producing CD4+Foxp3+ Treg cells can be generated upon polarization by cytokines such as IL-6 [14] [15] [16] .
The observed Th17 plasticity of Treg cells has raised the possibility that the stability of Foxp3+ Treg cells may play a potential pathogenic role at sites of inflammation. Treg cells with the plasticity of producing the proinflammatory cytokine IL-17 have been detected in normal human peripheral blood as well as in inflamed intestinal mucosa in patients with Crohn's disease [16, 18] . However, conflicting data exist regarding the functions of the IL-17-producing Treg population.
Previous studies have reported that the induction of IL-17 expression in Treg cells under inflammatory conditions was accompanied by impaired or lost suppressive function [26, 27] 6 potentially contribute to the pathogenesis of the disease [18] . To date, the exact role of Treg plasticity in immunoregulation is unclear, and the presence and clinical significance of the IL-17-producing Treg subset in RA remains unknown.
In the present study, we investigated the CD4+ Foxp3+ IL-17-producing Treg cell in patients with RA. This Treg population exhibited phenotypic characteristics of both Treg and Th17 cells, and retained potent suppressive activity in peripheral blood.
However, these Treg cells in RA synovial site lost suppressive activity. The expansion of this Treg population was promoted by the inflammatory cytokines IL-6 and IL-23, which were abnormally elevated in patients with RA. Moreover, the peripheral IL-17-producing Treg subset was associated with decreased RA disease activity, suggesting that these Treg cells are negative regulators in RA peripheral blood, but they might be pathogenic in RA synovial sites..
MATERIALS AND METHODS

Flow cytometry
Isolated PBMCs were stained for CD4 expression using a PE-CF594-labeled anti-human-CD4 antibody, for CD127 expression using a PerCP-Cy5.5-labeled anti-human-CD127 antibody, and for CD25 expression using a PE-Cy7-labeled anti-human-CD25 antibody (all antibodies from BD Pharmingen, San Diego, CA, USA). The expression of CTLA-4, IL-10, CD161, and CCR6 was examined using FITC-labeled monoclonal antibodies (BD Pharmingen). To analyze cytokine production, cells were stimulated and incubated for 5 h with 50 ng/ml phorbol 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 8 and healthy controls ( Figure 1A) , and the frequency of IL-17-producing CD4+ Foxp3+ Treg cells was significantly higher in patients with RA than in healthy controls ( Figure 1B) . Notably, in patients with RA, there is no significant correlation between IL-17-producing Treg cells and CD4+ Foxp3+ Treg cells ( Figure 1C ), and this IL-17-producing Treg population showed significantly positive correlation with Th17 cells ( Figure 1D ). We further examined the IL-17 producing Treg cell frequency in matched synovial fluid and peripheral blood from RA patients, and found that the frequency of this Treg subset was significantly elevated in synovial fluid ( Figure 1E and Supplementary Figure 1 ).
A previous study has defined three cell fractions with different functional characteristics in CD4+CD25+ Treg cells with CD45RA and Foxp3 expression [21] , Figure 1F upper panel]. Our study showed that more than 60% of IL-17 producing Treg cells were enriched in CD45RA-Foxp3 low "non-Treg" fraction, and around 30% IL-17 producing Treg cells distributed in CD45RA+ Foxp3 low "resting Treg" fraction.
Few Tregs in CD45RA-Foxp3 hi "activating Treg" fraction expressed IL-17 ( Figure   1F lower panel).
IL-17-producing Treg cells from the peripheral blood of patients with RA exhibited phenotypic characteristics of both conventional Th17 and Treg cells
To examine the phenotypic characteristics of the IL-17-producing CD4+ Foxp3+
Treg cells, we used flow cytometry to assess the expression of Foxp3 and surface markers or cytokines known to be associated with either Th17 or Treg cells. The expression levels of the Treg-associated regulatory molecules CTLA-4 and IL-10  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Figure 3A ). Because IL-6 and IL-23 together promote the development and expansion of Th17 cells [9] [10] [11] , elevated levels of these two cytokines in the sera of patients with RA may also provide the polarizing environment for the expansion of IL-17-producing Treg cells. To test this hypothesis, CD4+CD25+ Treg cells from the peripheral blood of patients with RA or healthy controls were purified by cell sorting and cultured in vitro in the presence of IL-2, IL-1β, and anti-CD3 and anti-CD28 antibody coated beads and supplemented with IL-6, IL-23, or both for 5 days. As expected, relatively low frequency of IL-17-producing Foxp3+ Treg cells was detected in cultures without the addition of polarizing cytokines. In the presence of IL-23, there was a slight but not significant increase in the IL-17-producing Treg frequency. However, under the polarizing culture condition supplemented with IL-6 or both IL-6 and IL-23, a significantly increased IL-17-producing Treg cell frequency was observed ( Figure 3B and C), implicating the polarizing function of IL-6 and IL-23 and that IL-6 should be a major player in the induction of IL-17-producing Treg cells. However, we did not observe any significant correlation between the serum levels of these polarizing cytokines and the IL-17 producing Treg subset (Supplementary Figure 2 ). Compared to Tregs from RA patients, Tregs from healthy controls showed similar plasticity toward Th17 under the same polarizing culture conditions ( Figure 3B and C), though the IL-17 producing Treg frequencies were modestly lower than those from RA patients without statistical significance. We also examined the expression of Th17-lineage specific transcription factor RORγt in Treg cells cultured in polarizing conditions. The RORgt levels were obviously increased when IL-6 or IL-6 together with IL-23 was added to culture ( Figure 3D ).
CD161 expression defined IL-17-producing Treg subset
We found that CD161, a surface marker of Th17 precursor cells [24] , was dramatically increased on IL-17 producing Treg cells ( Figure 2) , and it could also be used as the surface marker to characterize IL-17 producing Treg cells ( Figure 4A ).
With CD161 expression, we sorted CD4+CD25+ Treg cells from RA peripheral blood into two subsets: CD4+CD25+CD161+ Treg and CD4+CD25+CD161-Treg ( Figure   4A 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 IL-17-producing Treg cells among CD4+ Foxp3+ Treg cells were negatively correlated with ESR (r = -0.50, p < 0.01), CRP (r = -0.32, p = 0.036), and total IgG (r = -0.371, p = 0.022) ( Figure 5A ). There were also weak but significant positive correlations between this subset and circulating complement levels (C3, r = 0.33, p = 0.048; C4, r = 0.32, p = 0.045; Figure 5A ), suggesting that C3 and C4 levels would decrease with fewer IL-17-producing Treg cells. No significant correlation was found with patient age, disease duration, anti-CCP antibody, RF-IgM, RF-IgG, total IgA, total IgM, tender joint count, swollen joint count, or DAS28. These correlations indicate that the increased ratio of IL-17-producing Treg cells is associated with milder inflammation in patients with RA, which suggests that the circulating IL-17
producing Treg subset plays a negative regulatory role in the autoimmunity of RA. In addition, the ratio of IL-17-producing Treg cells was significantly lower in CD4+
Treg cells from patients with high RA disease activity (DAS28 > 5.1) than in cells from patients with intermediate or low disease activity (DAS28 < 5.1; Figure 5B ).
These results were consistent with our data from in vitro suppressive assays, suggesting that circulating IL-17-producing Treg cells in patients with RA retain their regulatory function in the inflammatory conditions of RA.
DISCUSSION
Recent studies have reported plasticity in the differentiation of Treg and Th17
cells. Foxp3+ Treg cells can be converted into inflammatory cytokine-producing cells
in the specific inflammatory microenvironment and may potentially contribute to 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 14 disease pathogenesis [14] [15] [16] [17] [18] [19] [20] . However, the contributions of Treg plasticity to the pathogenesis of autoimmune diseases require further study. In this study, we report for the first time the identification of IL-17-producing CD4+ Foxp3+ Treg cells in patients with RA. The frequency of this IL-17-producing Treg population is significantly increased in peripheral blood and synovial fluid of RA patients compared with that in healthy controls, which suggests that this Treg cell subset is associated with RA pathology.
We evaluated the distribution of IL-17 producing Treg in CD4+CD25+ Treg subpopulations defined with different CD45RA and Foxp3 expression by Sakaguchi group [21] . The majority of IL-17 producing Treg cells (over 60%) were from the CD45RA-Foxp3 low "non-Treg" fraction, which was considered transiently and unstably expressing Foxp3 and was shown to lack suppressive activity and had Th17 cell potential [21] , while relatively fewer IL-17 producing Treg cells were also distributed in the CD45RA+ Foxp3 low "resting Treg" fraction (around 30%) and
CD45RA-Foxp3 hi "activating Treg" fraction (less than 10%), both of which stably expressed Foxp3 and were suppressive [21] . This result clearly revealed that IL-17 15 population and originated from CD161+ naïve T cells [24] . In this study, we also identified CD161 as the key surface marker to characterize IL-17 producing Treg cells.
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Cytokine detection
IL-6 and IL-23 in serum were measured by standard enzyme-linked immunosorbent assays (ELISA; R&D Systems, Minneapolis, MN, USA).
Clinical data and inflammation marker analysis
All patients were assessed for complete clinical data including age, sex, disease duration, tender joint count, swollen joint count, global visual analog scale score, immunoglobulins (IgG, IgM, IgA), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), anti-keratin antibodies (AKA), anti-perinuclear factor (APF), anti-citrullinated peptide (anti-CCP) antibodies, rheumatoid factor (RF)-IgM, and RF-IgG.
The ESR was evaluated using the Westergren method. Values of 15 mm/h for males and 20 mm/h for females were considered normal. CRP and immunoglobulins were determined using immunonephelometry. Values >7.9 mg/l for CRP were considered positive. Anti-CCP antibodies, RF-IgM, and RF-IgG were tested by ELISA, with normal ranges of 0-5 U/ml, 0-120 U/ml, and 0-110 U/ml, respectively.
The DAS28 was calculated as previous described [19] .
Statistical analysis
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RF
